A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

As summer kicks into full gear and people are spending more time outside, there's one thing on many people's minds—ticks.

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

RSV M protein interacts with host cell membranes, holding together the virus’s filamentous structure and coordinating viral components and other proteins — including RSV F proteins.

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the disease.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

New RSV vaccine, treatment linked to dramatic fall in baby hospitalizations CDC study finds big declines in hospitalizations—and they may be underestimates.

Please provide your email address to receive an email when new articles are posted on . The FDA approved the monoclonal antibody clesrovimab-cfor for preventing RSV disease in babies. Unlike ...